|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 5,602,162: Scope, Claims, and Landscape
United States Patent 5,602,162, titled "Substituted indole derivatives," was granted on February 11, 1997, to Hoffmann-La Roche, Inc. The patent covers a class of chemical compounds with potential therapeutic applications, primarily focusing on serotonin receptor modulation.
What Does United States Patent 5,602,162 Claim?
The patent's claims define the specific chemical structures and their uses that are protected. Understanding these claims is crucial for assessing the patent's breadth and potential for infringement.
What are the Key Chemical Structures Claimed?
The core of the patent's claims revolves around a specific class of substituted indole derivatives. These compounds share a common indole ring structure but differ in their substituents at various positions, leading to distinct pharmacological profiles.
- Indole Core: The patent protects compounds containing an indole nucleus. This bicyclic structure is a common pharmacophore in many biologically active molecules.
- Substitutions: The claims specify various substituent groups that can be attached to the indole ring at positions 1, 2, 3, 4, 5, 6, or 7. These substituents are critical for determining the compound's interaction with biological targets.
- Position 1: The claims allow for an alkyl group, an aralkyl group, or an acyl group at this position.
- Position 2: Substitutions at position 2 can include a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an amino group, or a nitro group.
- Position 3: This position can be substituted with an alkylidene group, an alkanoyl group, or a group of the formula -X-R, where X is oxygen or sulfur and R is an alkyl or aralkyl group.
- Positions 4, 5, 6, 7: These positions on the benzene ring of the indole can be substituted with halogens, alkyl groups, alkoxy groups, nitro groups, or amino groups.
The patent provides specific examples of compounds within these defined parameters, illustrating the breadth of the protected chemical space. For instance, Claim 1 broadly defines the generic structure, while subsequent claims may narrow down specific ranges of substituents or preferred embodiments.
What Therapeutic Uses are Protected?
The patent claims not only the chemical compounds but also their therapeutic applications. The primary focus is on modulating serotonin receptors, which are implicated in a wide range of physiological processes and diseases.
- Serotonin Receptor Modulation: The compounds are claimed for their ability to act as agonists or antagonists of various serotonin (5-HT) receptor subtypes. These include, but are not limited to, 5-HT1A, 5-HT1D, 5-HT2A, and 5-HT3 receptors.
- Treatment of Central Nervous System (CNS) Disorders: The patent suggests the use of these compounds for treating conditions affecting the CNS. This includes:
- Psychiatric Disorders: Depression, anxiety disorders, panic attacks, and schizophrenia.
- Neurological Disorders: Migraine, cluster headaches, and potentially conditions involving neurodegeneration.
- Other Potential Applications: The claims may also extend to the treatment of gastrointestinal disorders, cardiovascular conditions, and other diseases where serotonin signaling plays a role. The specific use often depends on the particular compound and its affinity for distinct serotonin receptor subtypes.
What is the Scope of United States Patent 5,602,162?
The scope of a patent is determined by its claims, which define the boundaries of the protected invention. A broad scope offers greater protection against competitors.
How Broad Are the Claims Regarding Chemical Structure?
The generic nature of the structure claims in United States Patent 5,602,162 provides a relatively broad scope. By defining ranges of substituents and positions, the patent covers a significant number of potential chemical entities that share the core indole scaffold and exhibit specific structural characteristics.
- Generic vs. Specific Claims: While the patent likely includes specific exemplified compounds, the broad generic claims are more significant in defining the overall scope. These generic claims encompass all compounds that fall within the defined structural parameters, even those not explicitly synthesized or tested at the time of filing.
- Flexibility in Substituents: The wide variety of permissible substituents and their positions allows for considerable structural diversity. This means that minor modifications to known compounds within these ranges could still fall under the patent's protection, posing a challenge for competitors seeking to design around the patent.
- "Markush" Claims: The use of generic language to define substituents often falls under what is known as "Markush" claims. These are common in pharmaceutical patents and allow for the protection of a genus of compounds rather than just a single molecule. The breadth of the Markush group (i.e., the variety of substituents allowed) dictates the scope.
What is the Scope of Therapeutic Applications Claimed?
The patent claims a range of therapeutic applications, primarily linked to the modulation of serotonin receptors. The scope here is defined by the identified medical conditions that the compounds are asserted to treat.
- Target Receptor Subtypes: The patent's scope covers compounds effective against specific 5-HT receptor subtypes. A patent claiming activity against a widely expressed or functionally important receptor subtype will generally have a broader therapeutic scope.
- Diseases and Conditions: The list of treated conditions, such as depression, anxiety, and migraine, reflects the perceived utility of the claimed compounds. The broader the range of validated therapeutic uses, the more comprehensive the patent's protection.
- Method of Treatment Claims: Patents typically include "method of treatment" claims, which protect the use of the patented compounds to treat specific diseases in humans or animals. This means that even if a competitor synthesizes a claimed compound for a different, non-patented use, they would still infringe if they marketed it for a patented use.
What is the Patent Landscape for United States Patent 5,602,162?
The patent landscape refers to the collection of existing patents and patent applications related to a specific technology or therapeutic area. Analyzing this landscape helps understand the competitive environment and potential freedom to operate.
What are the Key Patents and Applications in this Area?
The landscape for serotonin receptor modulators, particularly those based on indole scaffolds, is extensive. United States Patent 5,602,162 is part of a broader patenting activity by pharmaceutical companies in this therapeutic space.
- Prior Art: Before patent 5,602,162, numerous patents and scientific publications would have disclosed indole derivatives and their potential pharmacological activities. The novelty and inventiveness of patent 5,602,162 would have been assessed against this prior art.
- Related Patents by Hoffmann-La Roche: It is common for a company to file multiple patents covering different aspects of a drug discovery program, including compound classes, specific compounds, synthetic methods, formulations, and new uses. Hoffmann-La Roche (now part of Roche Holding AG) has a history of research in CNS-acting drugs.
- Competitor Patents: Other major pharmaceutical companies actively researched serotonin receptor modulators. Key competitors would include companies like Eli Lilly, Pfizer, GlaxoSmithKline, and Novartis. Their patent portfolios would cover similar or overlapping chemical spaces and therapeutic targets.
- Subsequent Patent Filings: Post-grant, further patent applications might have been filed by Hoffmann-La Roche or others to cover:
- New Chemical Entities (NCEs): Derivatives or analogs of the compounds claimed in 5,602,162 with improved properties.
- New Formulations: Novel delivery systems or dosage forms.
- New Indications: Use of the compounds for treating additional diseases or conditions.
- Polymorphs and Salts: Specific crystalline forms or salt forms of the active pharmaceutical ingredient (API) that offer advantages.
What is the Expected Patent Expiration Date?
United States patents generally have a term of 20 years from the date of application filing, subject to certain adjustments.
- Application Filing Date: The patent was granted on February 11, 1997. To determine the expiration date, the original application filing date is required. Assuming a typical filing date prior to grant, the patent would have expired approximately 20 years after that filing date. For a patent granted in 1997, the application likely was filed in the mid-1990s.
- Estimated Expiration: Based on a typical prosecution timeline, if the application was filed in, for example, 1994, the patent would have expired around 2014 (1994 + 20 years). If filed in 1995, it would have expired around 2015. Without the exact filing date, a precise expiration date cannot be stated, but it would have been in the mid-to-late 2010s.
- Patent Term Adjustments (PTA) and Extensions (PTE): In some cases, patent terms can be extended due to delays in prosecution at the USPTO (PTA) or regulatory review periods for pharmaceuticals (PTE). These extensions, if granted, would push the expiration date further into the future. For a patent granted in 1997, the potential for significant PTE related to a drug approval is less likely unless the patent covered a specific drug approved much later.
Who Are the Potential Infringers?
Potential infringers are entities that manufacture, use, sell, offer to sell, or import into the United States subject matter that falls within the scope of the patent claims.
- Generic Drug Manufacturers: Companies that produce generic versions of drugs that utilize the chemical structures or therapeutic methods protected by the patent. Once the patent expires, generic manufacturers can seek to market their versions.
- Other Pharmaceutical Companies: Competitors developing new drugs with similar mechanisms of action or chemical structures. They may infringe if their compounds or methods fall within the patent's claims, even if they are not developing a direct generic equivalent.
- Research Institutions and Contract Research Organizations (CROs): While typically engaged in research, if they synthesize or supply compounds that fall within the patent's claims for commercial purposes related to therapeutic applications, they could be considered infringers.
- Companies Developing Non-Prescription Products: If the patented compounds have applications in over-the-counter (OTC) products or dietary supplements that fall under the claimed therapeutic uses, manufacturers in these sectors could also be infringing.
Key Takeaways
United States Patent 5,602,162 covers a class of substituted indole derivatives designed to modulate serotonin receptors for therapeutic applications, primarily in CNS disorders. The patent's broad scope, defined by its generic chemical structure claims and the range of claimed therapeutic uses, provided significant protection to Hoffmann-La Roche. While the patent has likely expired based on its grant date, understanding its scope and the landscape of related patents is crucial for navigating freedom-to-operate and identifying potential competitive strategies in the serotonin modulator market.
FAQs
1. What is the primary mechanism of action claimed by patent 5,602,162?
The primary mechanism of action claimed is the modulation of serotonin (5-HT) receptors, acting as agonists or antagonists for subtypes such as 5-HT1A, 5-HT1D, 5-HT2A, and 5-HT3.
2. Does patent 5,602,162 cover a specific drug, or a class of compounds?
The patent covers a class of substituted indole derivatives, defined by generic chemical structure claims, rather than a single specific drug. It protects a genus of compounds with potential therapeutic uses.
3. What are the key therapeutic areas associated with this patent?
The key therapeutic areas are those related to central nervous system (CNS) disorders, including depression, anxiety disorders, panic attacks, schizophrenia, migraine, and cluster headaches.
4. When did patent 5,602,162 expire?
Based on its grant date of February 11, 1997, and assuming a typical application filing date in the mid-1990s, the patent's 20-year term would have expired in the mid-to-late 2010s. Precise expiration requires the original application filing date and any potential patent term adjustments or extensions.
5. Can a company develop a drug with a similar chemical structure to those claimed in patent 5,602,162 today?
After patent expiration, the compounds and methods claimed enter the public domain. However, new developments, such as novel formulations, specific therapeutic uses not previously claimed, or manufacturing processes, could be independently patentable. Competitors must carefully assess the specific claims of expired patents and any potentially still-active patents in the field to ensure freedom to operate.
Citations
[1] Hoffmann-La Roche, Inc. (1997). United States Patent 5,602,162: Substituted indole derivatives. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
